Human Geranylgeranyl Diphosphate Synthase
cDNA CLONING AND EXPRESSION*

Tsuyoshi Kuzuguchi, Yuiko Morita, Ikuko Sagami, Hiroshi SagamiDagger , and Kyozo Ogura

From the Institute for Chemical Reaction Science, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai, 980-8577, Japan

    ABSTRACT
Top
Abstract
Introduction
References

Geranylgeranyl diphosphate (GGPP) synthase (GGPPSase) catalyzes the synthesis of GGPP, which is an important molecule responsible for the C20-prenylated protein biosynthesis and for the regulation of a nuclear hormone receptor (LXR·RXR). The human GGPPSase cDNA encodes a protein of 300 amino acids which shows 16% sequence identity with the known human farnesyl diphosphate (FPP) synthase (FPPSase). The GGPPSase expressed in Escherichia coli catalyzes the GGPP formation (240 nmol/min/mg) from FPP and isopentenyl diphosphate. The human GGPPSase behaves as an oligomeric molecule with 280 kDa on a gel filtration column and cross-reacts with an antibody directed against bovine brain GGPPSase, which differs immunochemically from bovine brain FPPSase. Northern blot analysis indicates the presence of two forms of the mRNA.

    INTRODUCTION
Top
Abstract
Introduction
References

Since Schmidt et al. (1) first detected the incorporation of a mevalonate-derived intermediate into protein in Swiss 3T3 cells, a number of prenylated proteins have been found in various organisms (2-6). The prenylation of these proteins is essential for their function in the cells (7-9), and the direct precursors of the prenyl moiety have been elucidated to be farnesyl diphosphate (FPP)1 and geranylgeranyl diphosphate (GGPP) by identifying protein-prenyltransferases in yeast and mammalian brains (10). Further, the number of geranylgeranylated proteins has been shown to be larger than that of farnesylated proteins (11-13). Recently, these shorter chain prenyl diphosphates also have been shown to be involved in the function of nuclear hormone receptors. Forman et al. (14) have isolated a mammalian orphan receptor, FXR, which forms a heterodimeric complex with RXR and identified farnesol and the related metabolites as effective activators of this complex (FXR·RXR). In a study of LXRalpha , another orphan nuclear receptor, they have also demonstrated that the DNA binding activity of LXRalpha ·RXR complex is inhibited by GGPP (15). These reports imply that not only FPP but also GGPP may contribute to signaling pathways in addition to protein prenylation.

FPP and GGPP are mevalonate-derived intermediates. The biosynthesis of mevalonate is regulated by a finely tuned mechanism, and the rate-limiting enzyme is 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in animal cells (16). FPP, whose carbon chain length is C15, is generally accepted to be the common intermediate occupying the branch point in the biosynthetic pathways to cholesterol, dolichol, ubiquinone, heme a, and farnesylated proteins. This compound is synthesized from dimethylallyl diphosphate by the action of FPP synthase (FPPSase), the most abundant and widely occurring prenyltransferase in mammalian tissues. FPPSase is composed of two identical subunits (17), and several FPPSase cDNAs have already been cloned in animals such as chicken, rat, and human (18). Genomic Southern blot analyses suggested that rat and human have multiple genes encoding divergent FPPSases (19, 20). On the other hand, GGPP, whose carbon chain length is C20, was initially thought to be supplied from FPP by the action of the FPPSase because FPPSase crystallized from avian liver had a poor but significant ability to synthesize GGPP from FPP and isopentenyl diphosphate (IPP) (21). Thereafter, we succeeded in isolating GGPP synthase (GGPPSase) in the different fraction from FPPSase by ion exchange chromatography of pig liver (22), rat liver (23), and bovine brain (24) cytosols. The GGPPSase has been purified from bovine brain in a homogeneous form (25) using a one-step procedure by affinity chromatography which contained an FPP analog as a ligand. The purified GGPPSase catalyzed a single reaction C15 right-arrow C20 and was composed of four or five subunits of identical size.

Considering that GGPP plays a role in the function of a nuclear hormone receptor and of geranylgeranylated proteins, it would be very important to characterize GGPPSase. Our original interest is in characterizing GGPPSase and FPPSase that occur in the same mammal or organ because GGPPSase could be regulated differently from FPPSase for their functions, although both of them catalyze the prenyl(C5)-transferring reaction. It is also interesting to learn the tissue-specific expression of GGPPSase because geranylgeranylated proteins have been reported to be rich specifically in brain (13). In the present study, we purified the GGPPSase of bovine brain in large amounts, isolated cDNAs of bovine and human GGPPSases using information from the bovine brain GGPPSase amino acid sequence, expressed the human GGPPSase in Escherichia coli, and characterized it. These analyses revealed that GGPPSase was a considerably different protein from FPPSase. Northern blot analysis indicated the presence of two mRNAs in various tissues.

    EXPERIMENTAL PROCEDURES

Materials-- [1-14C]IPP (55 mCi/mmol) and [alpha -32P]dCTP (6,000 Ci/mmol) were purchased from Amersham Pharmacia Biotech. [1-3H] GGPP (20 Ci/mmol), and [1-3H]geranylgeranyl monophosphate (15 Ci/mmol) were purchased from American Radiolabeled Chemicals Inc. Ex-Taq DNA polymerase was obtained from Takara Shuzou. Z,E,E-Geranylgeraniol was given by the Kuraray Corp. IPP, geranyl diphosphate (GPP), E, E-FPP, and E,E,E-GGPP were prepared as described in a previous report (26). Potato germ acid phosphatase (type I) was obtained from Sigma. All other chemicals were of reagent grade. Butyl-Toyopearl was obtained from Toyo Soda Co. Mono Q and Superdex 200 HR 10/30 were obtained from Amersham Pharmacia Biotech. Affinity gels with a geranylmethyl phosphonophosphate ligand and with a farnesylmethyl phosphonophosphate ligand were prepared by the method of Bartlett et al. (27). Bovine brain was obtained from a local slaughterhouse. Goat anti-guinea pig IgG heavy and light chain (alkaline phosphatase conjugate) were obtained from Bethyl Laboratories Inc. Guinea pig polyclonal antibodies were obtained by directing against purified bovine brain GGPPSase and FPPSase.

Enzyme Preparation-- Bovine brain was homogenized with a Polytron homogenizer in 50 mM Tris-HCl buffer (pH 7.5) containing 0.1 mM leupeptin, 0.2 mM phenylmethanesulfonyl fluoride, 1 mM EDTA, and 1 mM EGTA. The crude homogenate was centrifuged at 14,000 × g for 30 min. The supernatant was fractionated with ammonium sulfate. For purification of GGPPSase, the fraction precipitating between 40 and 60% saturation of ammonium sulfate was subjected to Butyl-Toyopearl chromatography. The elution from a Butyl-Toyopearl column was performed with a downward linear gradient from 15 to 0% saturation of ammonium sulfate. The fractions containing GGPPSase activities were pooled, concentrated, and dialyzed against 10 mM BisTris buffer (pH 7.0) containing 10 mM 2-mercaptoethanol and 1 mM MgCl2. The dialyzed fraction was then applied to an affinity column with a farnesylmethyl phosphonophosphate ligand. The GGPPSase was eluted with a linear gradient of FPP to 0.5 mM. The active fractions were pooled and then applied directly to a Mono Q column and eluted with a linear gradient of NaCl to 0.5 M. The GGPPSase was eluted at 0.15 M NaCl. For purification of FPPSase, the fraction precipitated between 30 and 40% saturation of ammonium sulfate was dialyzed against 10 mM PIPES buffer (pH 7.0) containing 10 mM 2-mercaptoethanol and 1 mM MgCl2 and applied to an affinity column with a geranylmethyl phosphonophosphate ligand. The FPPSase was eluted with l mM inorganic diphosphate. The active fractions were purified further by Mono Q chromatography.

Enzyme Assay-- The standard assay mixture contained, in a final volume of 0.1 ml, 50 mM potassium phosphate buffer (pH 7.0), 2 mM dithiothreitol, 5 mM MgCl2, 20 µM [1-14C]IPP, 25 µM GPP or FPP, and an appropriate amount of enzyme fraction. The mixture was incubated at 37 °C for 15 min and terminated by the addition of 0.30 ml of a mixture of concentrated HCl:methanol (4:1) followed by a 15-min incubation at 37 °C. The hexane-soluble hydrolysates were analyzed in a liquid scintillation fluid. For product analysis, the reaction products were extracted with 0.1 ml of 1-butanol saturated with water. The extracts were treated with potato acid phosphatase (2.4 units, 2.2 mg) according to the method of Fujii et al. (28). After incubation at 37 °C for 6 h, the hydrolysates were extracted with hexane and analyzed on a silica gel plate and a reverse phase C18 plate in a solvent system of toluene:ethyl acetate (9:1) and in a solvent system of acetone:water (7:1), respectively. The hydrolysates were also analyzed by the two-plate thin layer chromatography (TLC) method (29). The positions of authentic standards were visualized with iodine vapor. The radioactivity of polyprenols developed on TLC was determined with a Fuji Bioimage Analyzer BAS 1000.

SDS-PAGE and Immunoblotting-- Proteins were analyzed on 10 or 14% polyacrylamide gels (1.0 mm) containing 0.1% SDS and transferred to a nitrocellulose membrane. FPPSase and GGPPSase were visualized using the specific antibodies and the secondary antibody conjugated to alkaline phosphatase.

Analysis of Amino Acid Sequence of Bovine Brain GGPPSase-- The bovine brain GGPPSase preparation purified by affinity chromatography as described above was subjected to 10% SDS-PAGE and electrotransferred to a polyvinylidene difluoride membrane. The membrane corresponding to a Ponsau Red-positive GGPPSase band was cut off and analyzed by automated Edman degradation after treatment of lysyl endopeptidase. The sequences obtained were as follows: KAYK (fragment 2), KHLSK (fragment 4), KMFK (fragment 9), KTQETVQRILLEPY (fragment 14), and KQIDARGGNP (fragment 15).

Amplification of DNA by PCR-- The primers used for PCR were commercially synthesized: primer-1 was TCCCATGGAGAAGACTCAA; primer-2, ACTCA(AG)GA(AG)ACAGT(ACGT)CA; primer-3, TT(CT)GT(AG)AA(CT)TC(AG)TT(CT)TACAA; and primer-4, TTACTTATTACAATTCGAAAA. The PCR mixture (50 µl) consisted of 0.5 ng of cDNA, 100 pmol of primers, 0.20 µM each deoxynucleotide triphosphate, and 1.25 units of Ex-Taq DNA polymerase. Thirty-five cycles of amplification (0.5 min at 94 °C for denaturation, 1 min at 50 °C for annealing, and 1 min at 72 °C for extension) were carried out by using a Perkin-Elmer thermalcycler. The amplified products were analyzed on 1.4% agarose electrophoresis and recovered from the gels by use of a Geneclean II kit (BIO 101). The products were ligated directly into a vector pT7 blue T, and the insert DNA sequence was analyzed using the Thermosequenase Cycle Sequence kit (Amersham Pharmacia Biotech US78500).

Expression in E. coli-- The 919-base pair DNA containing human GGPPSase cDNA was isolated from pT7 blue T vector after double digestion with NcoI and BamHI, and the fragment was ligated into the NcoI and BamHI sites of a bacterial expression vector pTrc 99A. E. coli JM109 cells transformed with the vector alone or with the plasmid containing human GGPPSase cDNA (pTrc-HGG) were grown in 50 ml of LB medium to an A600 of 0.5. Isopropyl 1-thio-beta -D-galactopyranoside (IPTG) was added to a final concentration of 0.4 mM, and after 2.5 h culture the cells were collected and suspended in 2.0 ml of the TE buffer (pH 8.0). The cell suspensions were sonicated with a Branson sonifier before centrifugation at 14,000 × g to remove unbroken cells. The supernatants were frozen in aliquots for protein determination, SDS-PAGE, and GGPPSase assays.

    RESULTS

Purification of Bovine Brain GGPPSase and No Cross-reactivity of an Anti-GGPPSase Antibody with FPPSase-- In a previous report (25) we described a one-step purification of GGPPSase from bovine brain. The GGPPSase fraction still contained several minor proteins. We tried to improve the purification procedure with a combination of several chromatographies including affinity chromatography. As a result, Butyl-Toyopearl chromatography completely separated GGPPSase from FPPSase and IPP isomerase. This enabled us to prepare the purified GGPPSase with large amounts. Table I shows the entire purification steps of GGPPSase and FPPSase. The former enzyme (297 µg) and the latter enzyme (725 µg) were purified with specific activities of 294 and 1,070 nmol/min/mg from 6.01 and 10.8 kg of bovine brain, respectively. Fig. 1A shows SDS-PAGE of the purified GGPPSase and FPPSase. The GGPPSase (35.0 kDa) migrated faster than the FPPSase (37.5 kDa), suggesting that the entire polypeptide chain length of GGPPSase is shorter than that of FPPSase unless a post-translationary modification is present. A polyclonal antibody directed against the GGPPSase did not recognize the FPPSase (Fig. 1B), and a polyclonal antibody directed against the FPPSase did not recognize the GGPPSase (Fig. 1C). The Western blot analysis of crude extracts did not show any positive protein bands with the anti-GGPPSase antibody. Only affinity-purified GGPPSase was recognized by the antibody, suggesting that the GGPPSase content in the brain is low and that the current antibody is either of low affinity or titer.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Purification of GGPPSase and FPPSase of bovine brain
GGPPSase and FPPSase were purified starting from 6.01 kg and 10.8 kg of bovine brain, respectively. One unit was defined as the activity required to synthesize 1 nmol of product min-1 at 37 °C. FPP and [1-14C]IPP were used as substrates for GGPPSase. GPP and [1-14C]IPP were used as substrates for FPPSase.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 1.   SDS-PAGE of FPPSase and GGPPSase from bovine brain. Panel A, after electrophoresis, the gel was stained with Coomassie Brilliant Blue. Lane 1, FPPSase; lane 2, GGPPSase; lane 3, mixture of FPPSase and GGPPSase. Panels B and C, after electrophoresis, FPPSase (lanes 1 and 3) and GGPPSase (lanes 2 and 4) were transblotted to a nitrocellulose membrane and detected with anti-GGPPSase antibody (panel B) and anti-FPPSase antibody (panel C).

Cloning of GGPPSase cDNA-- Edman analysis of the purified bovine brain GGPPSase suggested that the NH2-terminal amino acid was blocked. Treatment of the enzyme protein with lysyl endopeptidase gave partial amino acid sequences of five fragments (fragments 2, 4, 9, 14, and 15). We searched various cDNAs registered in GenBank and found 22 partial human cDNA fragments as sequence homologs to a Neurospora crassa GGPPSase gene. Based on the sequence homology, we arranged the human cDNA fragments as shown in Fig. 2. The amino acid sequences KTQETVQRILLEPY (fragment 14) and KHLSKMFK (fragments 4 and 9) identified in bovine brain GGPPSase were found in the deduced amino acid sequence of these fragments. Based on the partial amino acid sequences of the bovine brain GGPPSase described above, we synthesized nucleotide primers (sense primer-2 and antisense primer-3).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 2.   Strategy for cloning human and bovine GGPPSase cDNA. Partial cDNA sequences similar to N. crassa GGPPSase registered in GenBank were arranged from the 5'-end in each tissue. A single line was arranged in the middle, considering the high frequency of the common sequence (closed bar). The left and right continuous DNA sequences contain stop codons TGA and TAA, respectively. Immediately below the two nucleotide sequences are the deduced amino acid sequences. The actual amino acid sequences (fragments 14, 4, and 9) determined by Edman degradation of purified bovine brain GGPPSase are underlined. Combinations of primers-1 (sense) and -4 (antisense) and of primers-2 (sense) and -3 (antisense) were used for PCRs.

PCR with primers-2 and -3 using human testis cDNA (CLONTECH) as a template gave an 875-base product. Sequence analysis revealed that this fragment contained the sequence of the partial human cDNA fragments picked up in Fig. 2. We synthesized sense primer-1 and antisense primer-4 containing a starting codon (ATG) and a stop codon (TAA), respectively. As expected, PCR of human testis cDNA with primers-1 and -4 gave a 919-base product that covered an entire coding sequence of human GGPPSase.

On the basis of the similarity of the peptide sequence between NH2-terminal and COOH-terminal human and bovine GGPPSases, we performed a PCR with a combination of primers-1 and -4 using bovine liver cDNA as a template. Multiple PCR products were obtained in this case. However, further amplification of the multiple PCR products with a combination of the inner primers (primers-2 and -3) gave an 875-base product on an agarose electrophoresis. The deduced amino acid sequence of the 875-base product contained all of the partial sequence (fragments 2, 4, 9, 14, and 15) determined by Edman degradation of purified bovine brain GGPPSase, indicating that the cDNA (875 base pairs) encodes a partial bovine brain GGPPSase.

Expression of human GGPPSase in E. coli-- To confirm that the human 919-base PCR product codes GGPPSase, we tried to express the protein and assay the enzyme activity. E. coli JM109 cells were transformed with the expression plasmid pTrc 99A containing the GGPPSase cDNA, and the cell extracts were subjected to SDS-PAGE. As shown in Fig. 3A, a polypeptide corresponding to 33 kDa was induced by the addition of IPTG. Western blot analysis showed that this polypeptide was specifically recognized by anti-bovine brain GGPPSase antibody (Fig. 3B). To determine whether the induced protein is active, the bacterial cell extracts were used as the enzyme source in GGPPSase assays. The enzymatic activity with a combination of FPP and [1-14C]IPP was enhanced about 40-fold in the expressed cells compared with the control cells as shown in Table II. The reaction products comigrated not only with the spot of geranylgeranyl monophosphate but also with that of GGPP on normal phase silica gel TLC (not shown). However, the hydrolysates by acid phosphatase treatment of the products moved with the spot of all-trans-geranylgeraniol on reverse phase C18 TLC (Fig. 3C) and normal phase TLC (not shown). These results indicate that the isolated cDNA codes an active GGPPSase protein. The expressed human GGPPSase protein was purified by Butyl-Toyopearl and Mono Q column chromatographies and by Superdex 200 gel filtration. The enzyme was purified as a single peak with a molecular mass of 280 kDa (Fig. 3D) on the gel filtration. The purified GGPPSase catalyzed the formation of GGPP, and the allylic substrate specificity for the enzyme is shown in Fig. 3E. Table III shows quantitative analysis of the enzymatic products. These results confirmed the identify of the expected 900-base cDNA as encoding human GGPPSase and the similar properties of human GGPPSase to bovine GGPPSase in the substrate specificity as characterized previously (25). It should be emphasized that the human GGPPSase also behaves as an oligomer composed of eight subunits of identical size (33 kDa) similar to bovine brain GGPPSase. Fig. 4A shows the cDNA sequence and the deduced amino acid sequence of human testis GGPPSase. The amino acid sequence predicted from the GGPPSase gene corresponds to a polypeptide chain with molecular mass of 34,870 Da. The human GGPPSase only showed 16% sequence identity with the known human FPPSase (Fig. 4B) but 49.2% identity in the consensus sequences (I, II, III, IV, and V) proposed for trans-prenyltransferase. The total homology between the nucleotide sequences was 27.8%. The GGPPSase had three potential N-glycosylation sites.


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 3.   Characterization of human GGPPSase expressed in E. coli. Panel A, SDS-PAGE analysis of human GGPPSase in E. coli. The cell extracts were electrophoresed on SDS-polyacrylamide gels. Lane 1, E. coli pTrc 99A; lane 2, E. coli pTrc-HGG (-IPTG); and lane 3, E. coli pTrc-HGG (+IPTG). Molecular mass standards are shown on the left. Panel B, Western blot analysis of human GGPPSase production in E. coli. Proteins on electrophoresis similar to panel A were transferred to a nitrocellulose membrane and probed with an antibody directed against purified bovine brain GGPPSase. Molecular mass standards are shown on the left. Lanes 1, 2, and 3 are the same as indicated in the legend to panel A. Panel C, reverse phase C18 TLC radioautograms of the hydrolysates obtained by phosphatase treatment of the products derived from FPP and [1-14C]IPP with crude extracts of E. coli pTrc 99A (lane 1), E. coli pTrc-HGG (-IPTG) (lane 2), or E. coli pTrc-HGG (+IPTG) (lane 3). The samples were developed in acetone:water (7:1). GGOH, geranylgeraniol (C20); FOH, farnesol (C15); Ori., origin; and S.F., solvent front. Panel D, gel filtration of human GGPPSase. The closed and open circles indicate the absorption at 280 nm and the enzyme activity with FPP and [1-14C]IPP, respectively. The inset shows SDS-PAGE stained with Coomassie Brilliant Blue of the active fractions. Molecular mass standards: a, ferritin 440,000; b, catalase 232,000; c, bovine serum albumin 67,000. Panel E, thin layer radiochromatograms of prenyl products with purified human GGPPSase. Enzymatic products were developed in isopropyl alcohol:ammonia:water (6:3:1). Lane 1, [1-14C]IPP alone; lane 2, dimethylallyl diphosphate + [1-14C]IPP; lane 3, GPP + [1-14C]IPP; lane 4, FPP + [1-14C]IPP.

                              
View this table:
[in this window]
[in a new window]
 
Table II
GGPPSase activity in E. coli extracts
GGPPSase activities were measured in extracts from cells (JM109) transformed with plasmids as indicated. pTrc-HGG shows a plasmid containing human GGPPSase cDNA in the pTrc 99A vector. Assays were carried out in the presence (+) and absence (-) of FPP.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Distribution of enzymatic products


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 4.   Primary structure of human GGPPSase. Panel A, cDNA and deduced amino acid sequences of human GGPPSase. The stop codon is TAA (*). The potential N-glycosylation sites are underlined. Panel B, comparison between human GGPPSase and FPPSase (P14324). Five consensus sequences (I, II, III, IV, and V) common to trans-prenyltransferase are underlined. The common amino acids between the two enzymes are boxed. Asterisks indicate the potential N-glycosylation sites in the GGPPSase sequence.

Multiple Transcripts Hybridized to a GGPPSase cDNA Probe-- Northern blotting analyses with 32P-labeled cDNA probes encoding the human testis GGPPSase revealed two sizes of mRNAs (about 1.5 and 3.1 kilobases) in various tissues (Fig. 5). These mRNAs were abundant in heart, skeletal muscle, and testis, with the shorter mRNA being the major species in these tissues. The amount of GGPPSase mRNA in the brain was lower than expected given the degree of enrichment of geranylgeranylated proteins in this organ (11).


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 5.   Tissue distribution of mRNA for human GGPPSase. Northern blots (CLONTECH) containing approximately 2 µg of poly(A)+ RNA/lane from 16 different human tissues were used. Hybridization was done at 68 °C for 1 h with a 32P-labeled cDNA probe (2 × 106 cpm/ml) for human GGPPSase. Filters were washed three times in 2 × SSC containing 0.05% SDS at room temperature for 10 min and twice in 0.1 × SSC containing 0.1% SDS at 50 °C for 20 min and exposed to an imaging plate overnight at room temperature. As a loading control, the same filters were then reprobed with random primed 32P-labeled oligonucleotides of human beta -actin cDNA (2 × 106 cpm/ml). The reprobed filters were exposed for 4 h at room temperature (lower panel). Size markers are indicated by the arrows. Muscle, skeletal muscle; Intestine, small intestine; Leukocyte, peripheral blood leukocyte. kb, kilobases.


    DISCUSSION

The original aim of our study was to learn how FPPSase and GGPPSase are different from each other because these enzymes catalyze a common isoprenyl-transferring reaction. Polyclonal antibodies directed against the two enzymes of bovine brain did not show any cross-reactivity with each other (Fig. 1). The immunochemical difference between these two proteins was confirmed with amino acid sequence comparison between the GGPPSase determined in this study and the known human FPPSase (30) (Fig. 4B). Five conserved amino acid motifs (I, II, III, IV, and, V) common to trans-prenyltransferases reported (18) were observed between the two enzymes, but the entire identity was only 16%. The human GGPPSase has three potential N-glycosylation sites, whereas human FPPSase has no such sites (30). Any potential N-glycosylation site is also not observed in the amino acid sequences of FPPSase of rat (19). It is not clear at present whether the GGPPSase is N-glycosylated. Human GGPPSase shows extremely high homology to other GGPPSases of bovine, Drosophila, and N. crassa (Fig. 6). Three potential N-glycosylation sites observed in human GGPPSase are also found in the bovine enzyme, and two of them are conserved in the insect enzyme, although two Asn-X-Ser/Thr motifs are found at different sites in the N. crassa enzyme.


View larger version (72K):
[in this window]
[in a new window]
 
Fig. 6.   Comparison of the deduced amino acid sequence of the human GGPPSase with several other GGPPSases. Human, human GGPPSase; Bovine, a partial sequence of bovine brain GGPPSase (T. Kuzuguchi, and H. Sagami, unpublished results); Drosophila, Drosophila melanogaster GGPPSase (AF049659); Neurospora, N. crassa GGPPSase (P24322). Consensus sequences shown below the five highly conserved sequence domains (I-V) proposed for trans-prenyltransferase by Chen et al. (18) are underlined. The numbers of amino acids are indicated on the left. Boxes enclose identical amino acids in at least three of the four sequences compared. Asterisks indicate the potential N-glycosylation sites in the human GGPPSase sequence.

Sheares et al. (20) reported that the expression of human FPPSase in Hep G2 cells is transcriptionally regulated: lovastatin, a potent inhibitor of HMG-CoA reductase, increased the level of the mRNA, whereas cholesterol in its 25-hydroxylated form or in low density lipoprotein particles reduced the amount of the mRNA, and mevalonate also decreased the mRNA levels. Similar regulation of HMG-CoA synthase, HMG-CoA reductase, and low density lipoprotein receptor had been already reported (16), suggesting a common control mechanism for these enzymes. Recently, Guan et al. (31) described differential, transcriptional regulation of the human gene encoding squalene synthase, which accepts FPP as a substrate, by variation in the level of cellular cholesterol. Concerning GGPPSase, which also accepts FPP as a substrate, the study on regulation is far behind those of the enzymes described above. Lutz et al. (32) have demonstrated that GGPP synthesis is specifically inhibited by GGPP, suggesting that the cellular GGPP pool may be regulated by product inhibition of GGPPSase. Our in vitro experiments using a purified bovine brain GGPPSase supported this regulation (25).

GGPP acts as a precursor for the C20 lipid moiety in prenylated proteins and also as a modulator for nuclear hormone receptor (LXRalpha ·RXR) complex formation. In the present study two mRNAs of GGPPSase were identified. Arrangement of several partial cDNA sequences registered in GenBank (Fig. 2) further implies the presence of more than two GGPPSase mRNAs. Therefore, the GGPP synthesis might be regulated at the transcriptional level of GGPPSase. Rilling et al. (11) have reported the content of geranylgeranylated proteins in mouse tissues; these proteins are severalfold rich in brain compared with those in liver, kidney, and lung. In human tissues, two GGPPSase mRNAs were also observed in those tissues. Although they did not describe the content of geranylgeranylated proteins in mouse heart, skeletal muscle, and testis, much higher contents of human GGPPSase mRNAs were detected in these tissues. Two kinds of protein geranylgeranyl transferase responsible for the synthesis geranylgeranylated proteins have been found and characterized in mammals. On Northern blot analysis for rat protein geranylgeranyl transferase II consisting of alpha  and beta  subunits (component B) and an escort protein (component A) (33, 34), the alpha  and beta  subunits mRNAs are abundant in heart and much lower muscle and testis. The escort protein mRNA is also abundant in heart, much lower in muscle, and not detectable in testis. In the case of the alpha  subunit of rat protein geranylgeranyl transferase I (35), which is the same protein as that of protein farnesyl transferase, the amount of the mRNA is rather low in heart and muscle, whereas the amount in testis is severalfold higher than in any other tissue. It would be difficult at present to explain the reason why the mRNA levels of these enzymes directly related to GGPP metabolism are regulated differently especially in these tissues.

It is very important to establish how many genes encode GGPPSase, which gene is transcripted in each tissue, and how each gene is regulated. FPPSase has been reported to be encoded by multiple genes (19, 20). Further analysis of mammalian GGPPSase will contribute to the understanding of a finely tuned mechanism of mevalonate pathway. Sepp-Lorenzino et al. (36) reported cell cycle-dependent differential prenylation of proteins. LXRalpha has been reported to display constitutive transcriptional activity that is negatively regulated with GGPP (15). It remains unclear how GGPP inhibits LXRalpha and contributes to signaling pathways. It would be also very interesting to know the regulation of GGPP formation in the process of embryonic development and cell differentiation.

    FOOTNOTES

* This research was supported in part by a grant-in-aid from the Ministry of Education, Science, Sports, and Culture of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AB017971.

Dagger To whom correspondence should be addressed. Tel.: 81-22-217-5622; Fax: 81-22-217-5620; E-mail: yasagami{at}icrs.tohoku.ac.jp.

    ABBREVIATIONS

The abbreviations used are: FPP, farnesyl diphosphate; GGPP, geranylgeranyl diphosphate; HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; FPPSase, FPP synthase; IPP, isopentenyl diphosphate; GGPPSase, GGPP synthase; GPP, geranyl diphosphate; BisTris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)-propane-1,3-diol; PIPES, 1,4-piperazinediethanesulfonic acid; TLC, thin layer chromatography; PAGE, polyacrylamide gel electrophoresis; PCR, polymerase chain reaction; IPTG, isopropyl 1-thio-beta -D-galactopyranoside.

    REFERENCES
Top
Abstract
Introduction
References
  1. Schmidt, R. A., Schneider, C. J., and Glomset, J. A. (1984) J. Biol. Chem. 259, 10175-10180[Abstract/Free Full Text]
  2. Clarke, S. (1992) Annu. Rev. Biochem. 61, 355-386[CrossRef][Medline] [Order article via Infotrieve]
  3. Stimmel, J. B., Deschenes, R. J., Volker, C., Stock, J., and Clarke, S. (1990) Biochemistry 29, 9651-9659[Medline] [Order article via Infotrieve]
  4. Maltese, W. A. (1990) FASEB J. 4, 3319-3328[Abstract/Free Full Text]
  5. Rine, J., and Kim, S.-H. (1990) New Biol. 2, 219-226[Medline] [Order article via Infotrieve]
  6. Takai, Y., Kaibuchi, K., Kikuchi, A., and Kawata, M. (1992) Int. Rev. Cytol. 133, 187-230[Medline] [Order article via Infotrieve]
  7. Itoh, T., Kaibuchi, K., Masuda, T., Yamamoto, T., Matsuura, Y., Maeda, A., Shimizu, K., and Takai, Y. (1993) J. Biol. Chem. 268, 3025-3028[Abstract/Free Full Text]
  8. Horiuchi, H., Kaibuchi, K., Kawamura, M., Masuura, Y., Suzuki, N., Kuroda, Y., Kataoka, T., and Takai, Y. (1992) Mol. Cell. Biol. 12, 4515-4520[Abstract]
  9. Kuroda, Y., Suzuki, N., and Kataoka, T. (1993) Science 259, 683-686[Medline] [Order article via Infotrieve]
  10. Boguski, M. S., and McCormick, F. (1993) Nature 366, 643-654[CrossRef][Medline] [Order article via Infotrieve]
  11. Rilling, H. C., Bruenger, E., Epstein, W. W., and Crain, P. F. (1990) Science 247, 318-320[Medline] [Order article via Infotrieve]
  12. Farnsworth, C. C., Gelb, M. H., and Glomset, J. A. (1990) Science 247, 320-322[Medline] [Order article via Infotrieve]
  13. Epstein, W. W., Lever, D., Leining, L. M., Bruenger, E., and Rilling, H. C. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 9668-9670[Abstract]
  14. Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., Evans, R. M., and Weinberger, C. (1995) Cell 81, 687-693[Medline] [Order article via Infotrieve]
  15. Forman, B. M., Ruan, B., Chen, J., Schroepfer, G. J., Jr., and Evans, R. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10588-10593[Abstract/Free Full Text]
  16. Goldstein, J. L., and Brown, M. S. (1990) Nature 343, 425-430[CrossRef][Medline] [Order article via Infotrieve]
  17. Ding, V. D., Sheares, B. T., Bergstrom, J. D., Ponpipom, M. M., Perez, L. B., and Poulter, C. D. (1991) Biochem. J. 275, 61-65[Medline] [Order article via Infotrieve]
  18. Chen, A., Kroon, P. A., and Poulter, C. D. (1994) Protein Sci. 3, 600-607[Abstract/Free Full Text]
  19. Clarke, C. F., Tanaka, R. D., Svenson, K., Wamsley, M., Fogelman, A. M., and Edwards, P. A. (1987) Mol. Cell. Biol. 7, 3138-3146[Medline] [Order article via Infotrieve]
  20. Sheares, B. T., White, S. S., Molowa, D. T., Chan, K., Ding, V. D.-H., Kroon, P. A., Bostedor, R. G., and Karkas, J. D. (1989) Biochemistry 28, 8129-8135[Medline] [Order article via Infotrieve]
  21. Reed, B. C., and Rilling, H. C. (1975) Biochemistry 14, 50-54[Medline] [Order article via Infotrieve]
  22. Sagami, H., Ishii, K., and Ogura, K. (1981) Biochem. Int. 3, 669-675
  23. Sagami, H., Korenaga, T., Ogura, K., Steiger, A., Pyun, H.-J., and Coates, R. M. (1992) Arch. Biochem. Biophys. 297, 314-320[Medline] [Order article via Infotrieve]
  24. Sagami, H., Korenaga, T., and Ogura, K. (1993) J. Biochem. (Tokyo) 114, 118-121[Abstract]
  25. Sagami, H., Morita, Y., and Ogura, K. (1994) J. Biol. Chem. 269, 20561-20566[Abstract/Free Full Text]
  26. Davisson, V. J., Woodside, A. B., and Poulter, C. D. (1985) Methods Enzymol. 110, 130-144[Medline] [Order article via Infotrieve]
  27. Bartlett, D. L., King, C.-H. R., and Poulter, C. D. (1985) Methods Enzymol. 110, 171-184[Medline] [Order article via Infotrieve]
  28. Fujii, H., Koyama, T., and Ogura, K. (1982) Biochim. Biophys. Acta 712, 716-718[Medline] [Order article via Infotrieve]
  29. Sagami, H., Kurisaki, A., Ogura, K., and Chojnacki, T. (1992) J. Lipid Res. 33, 1857-1861[Abstract]
  30. Wilkin, D. J., Kutsunai, S. Y., and Edwards, P. A. (1990) J. Biol. Chem. 265, 4607-4614[Abstract/Free Full Text]
  31. Guan, G., Dai, P., and Shechter, I. (1998) J. Biol. Chem. 273, 12526-12535[Abstract/Free Full Text]
  32. Lutz, R. J., McLain, T. M., and Sinensky, M. (1992) J. Biol. Chem. 267, 7983-7986[Abstract/Free Full Text]
  33. Armstrong, S. A., Seabra, M. C., Südhof, T. C., Goldstein, J. L., and Brown, M. S. (1993) J. Biol. Chem. 268, 12221-12229[Abstract/Free Full Text]
  34. Andres, D. A., Seabra, M. C., Brown, M. S., Armstrong, S. A., Smeland, T. E., Cremers, F. P. M., and Goldstein, J. L. (1993) Cell 73, 1091-1099[Medline] [Order article via Infotrieve]
  35. Chen, W.-J., Andres, D. A., Goldstein, J. L., and Brown, M. S. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 11368-11372[Abstract]
  36. Sepp-Lorenzino, L., Rao, S., and Coleman, P. S. (1991) Eur. J. Biochem. 200, 579-590[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.